Equities

DNAC

KYG8253W1096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.12 ^USD	-21.77%		+3.92%	-78.46%

2022	Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
2022	ProKidney Completes SPAC Merger With Social Capital Suvretta Holdings; Shares to Start Nasdaq Trading	MT

Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 12, 2022 at 06:15 am EDT

Social Capital Suvretta Holdings Corp. III reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 2.27 million compared to USD 0.000143 million a year ago.
For the six months, net loss was USD 6.25 million.

Latest news about SOCL CAPI

Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
ProKidney Completes SPAC Merger With Social Capital Suvretta Holdings; Shares to Start Nasdaq Trading	22-07-12	MT
Social Capital Suvretta Holdings Corp. III(NasdaqCM:DNAC) dropped from NASDAQ Composite Index	22-07-12	CI
ProKidney LLC completed the acquisition of Social Capital Suvretta Holdings Corp. III from SCS Sponsor III LLC, Millennium Management LLC, Adage Capital Management, L.P. and others in a reverse merger transaction.	22-07-10	CI
Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Social Capital Suvretta Holdings Corp. III Issues an Unsecured Promissory Note	22-04-22	CI
Social Capital Suvretta Holdings Corp. III announced that it has received $1.5 million in funding from SCS Sponsor III LLC	22-04-19	CI
Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Ten Months Ended December 31, 2021	22-03-24	CI
ProKidney to Become Publicly Traded via SPAC Merger With Social Capital Suvretta	22-01-18	MT
Palihapitiya-backed SPAC to take biotech ProKidney public in $2.6 bln deal	22-01-18	RE
Palihapitiya-backed SPAC to take ProKidney public in over $2 bln deal	22-01-18	RE
ProKidney LLC executed the non-binding letter of intent to acquire Social Capital Suvretta Holdings Corp. III from SCS Sponsor III LLC, Millennium Management LLC, Adage Capital Management, L.P. and others in a reverse merger transaction.	22-01-17	CI
Social Capital Suvretta Said in Merger Talks With Akili Interactive, ProKidney	22-01-10	MT
Certain Class B Ordinary Shares of Social Capital Suvretta Holdings Corp. III are subject to a Lock-Up Agreement Ending on 27-DEC-2021.	21-12-26	CI
Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Third Quarter and Seven Months Ended September 30, 2021	21-11-15	CI
Social Capital Suvretta Holdings Corp. III Announces Board Changes	21-09-24	CI
Social Capital Suvretta Holdings Corp. III announced that it has received $6.4 million in funding	21-07-01	CI
Social Capital Suvretta Holdings Corp. III(NasdaqCM:DNAC) added to NASDAQ Composite Index	21-07-01	CI
DNAC : Social Capital Suvretta Holdings Corp. III Shares Climb in Nasdaq Debut	21-06-30	MT

Chart SOCL CAPI

Duration

Period

More charts

Company Profile

Social Capital Suvretta Holdings Corp. III is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It has not selected any specific business combination target and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company intend to focus its search for a target business operating in the biotechnology industry and within the organ space subsector of such industry. The Company neither engages in any business operations nor generates any revenues.

Sector

More about the company